Houston, Texas
United States
6
2023-08-31
4
2025-03-04
These are the the leading inventors for applications assigned to MEMGEN, Inc.:
MEMGEN, Inc. based in Houston, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
ONCOLYTIC VIRUS BOOSTS T CELL RESPONSE FOR EFFECTIVE TIL THERAPY
#2 | 2022-03-24Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccine
#3 | 2021-09-02 ✅ Patent 12,239,666 granted on 2025-03-04Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
#4 | 2021-05-06 ✅ Patent 11,951,141 granted on 2024-04-09Replication-enhanced oncolytic adenoviruses
#5 | 2020-11-12 ✅ Patent 12,171,803 granted on 2024-12-24Methods of CD40 and toll like receptor immune activation
#6 | 2020-05-28 ✅ Patent 11,594,135 granted on 2023-02-28Methods of CD40 activation and immune checkpoint blockade
Also check out MEMGEN, Inc.'s (Houston, United States) applicant profile with 3 patent applications submitted.
310037 ⎘